962 Circulation Vol 88, No 3 September 1993 (15%), III (61%), or IV (12%) according to the Canadian Heart Association classification. Recent myocardial infarction (within 1 month) occurred in 14% of patients, and significant coronary artery disease (more than 50% diameter stenosis) was limited to one vessel in 38%, two vessels in 32%, and three vessels in 30% of patients. Prior coronary artery bypass surgery had been performed in 21% of patients. The mean left ventricular ejection fraction was 49±11%.
Baseline Angiographic Findings
Of 116 lesions treated, 81 (70%) were de novo lesions, and 35 (30%) were restenosis lesions that had developed after prior PTCA. The target lesion was located in the left main coronary artery in 7%, the left anterior descending coronary artery in 35%, the left circumflex or obtuse marginal arteries in 15%, the right coronary artery in 39%, and a saphenous vein bypass graft in 3%. The target lesion was located in a proximal vessel segment in 62%, a midvessel segment in 30%, and a distal vessel segment in 8%. Target lesions were selected on the basis of their suitability for conventional PTCA and alternative interventional techniques. Patients with acute myocardial infarction, with lesions more than 25 mm long, or with lesions in degenerated vein grafts were excluded. Coronary Atherectomy Procedure All coronary atherectomy procedures were performed according to a protocol approved by the Human Investigations Committee of William Beaumont Hospital. A temporary transvenous pacemaker was inserted prophylactically in all patients with target lesions in the right coronary artery. A standard 9F or 1OF angioplasty guiding catheter was positioned at the vessel ostium, and a 0.014-in. 300-cm-long angioplasty guide wire (Advanced Cardiovascular Systems, Santa Clara, Calif) was advanced across the lesion. This wire was then exchanged for the rigid stainless-steel 0.009-in. Rotablator guide wire (Heart Technologies, Bellevue, Wash) by using a 2.5F infusion catheter (Cordis, Miami, FHa). Once the Rotablator guide wire was in the proper position, the Rotablator burr (Heart Technologies) was advanced into the guiding catheter (burrs less than 2.0 mm were used with 9F guiding catheters and burrs of 2.0 mm or more were used with 1OF guiding catheters). The burr was then slowly advanced across the lesion using gentle forward pressure, while rotating at 170 000 to 200 000 rpm. Generally, two to five passes were performed, lasting 5 to 45 seconds. After MRA, repeat angiography was performed, and adjunctive PICA was used if necessary to achieve a residual stenosis of less than 50% (Fig 1) .
Several aspects of this procedure should be emphasized. First, it is important to place the Rotablator guide wire tip into the distal vessel to ensure that the stiff portion of the guide wire is across the lesion, so that the Rotablator is not activated along the flexible portion of the wire. Second, the rotational speed should not be allowed to fall below 130,000 rpm, and excessive forward force and "jack-hammering" should be avoided. Finally, the selection of burr sizes is largely empiric, but for longer segments of disease or de novo lesions, we generally recommend sequential increases in burr sizes. 
Medications
All patients were pretreated with aspirin, long-acting nitrates, and calcium channel blockers at least 24 hours before the procedure. 3-Blockers were discontinued if possible to minimize the potential for coronary vasospasm. After insertion of the arterial sheath, 10 000 units heparin was administered, and additional heparin was given throughout the procedure to maintain the activated clotting time at more than 300 seconds. Sublingual nifedipine and nitroglycerin infusion were given before atherectomy, and intracoronary nitroglycerin was administered after placement of the guiding catheter in the vessel ostium. The importance of this vigorous antispasm regimen cannot be overemphasized. After the procedure, patients were treated with overnight infusions of heparin and nitroglycerin, and long-acting nitrates, calcium channel blockers, and aspirin were prescribed for at least 6 weeks.
Quantitative Angiography
The single view that identified the most severe stenosis was selected for analysis. Measurements tDefined as more than two 900 bends proximal to lesion. *As described by Ellis and colleagues.2 more after MRA, and overall procedural success was defined as a final diameter stenosis of less than 50% in the absence of a major complication (death, emergency bypass surgery, or Q-wave myocardial infarction). Non-Q-wave myocardial infarction was defined as elevation of creatine kinase more than three times the upper limit of normal in the absence of new pathological Q waves. No-reflow was defined as delayed antegrade flow (TIMI grade of less than 2) in the absence of a clear explanation for impaired flow (dissection, thrombus, spasm) at or adjacent to the original lesion. Angiographic restenosis was defined as a diameter stenosis of more than 50% at the time of follow-up. The RLD-D ratio was defined as the ratio of the residual lumen diameter (RLD) immediately after MRA to the final diameter (D) of the Rotablator burr. The RLD-D ratio is a measure of the relative lumen diameter achieved, normalized for the size of the burr, and is a direct measure of efficiency of lumen enlargement.
Statistical Analysis
Data are reported as mean±SD values. Comparisons were made using Student's t test for continuous variables. P<.05 was considered significant.
Results

Baseline Lesion Morphology
Using the modifications of the American College of Cardiology/American Heart Association (ACC/AHA) Task Force classification proposed by Ellis and colleagues,2 lesions were classified as A (20%), B1 (31%), B2 (45%), and C (4%) ( Table 1) . Complex lesion morphology (class B or C) was present in 80% of lesions, including eccentricity in 38%, aorto-ostial or origin location in 26%, moderate or severe angulation in 20%, and calcification in 17% of lesions (Fig 1) . 
Clinical Complications
Despite the observation of significant angiographic complications in nearly 40% of lesions, clinical sequelae were much less frequent (Table 4). As described above, 5 lesions in 5 patients were totally occluded at the completion of the procedure, mandating emergency bypass in 2 patients (1.9%) and conservative therapy without surgical intervention in 2 patients (1.9%). One (1.0%) of these 5 patients, who was not believed to be a surgical candidate, died within 24 hours despite percutaneous cardiopulmonary bypass (CPS). All 5 patients suffered Q-wave myocardial infarction (4.8%). Three patients with transient no-reflow or distal embolization had non-Q-wave myocardial infarction (2.9%). A total of 7 patients were placed on percutaneous support (6.7%), including 2 patients (1 intra-aortic balloon pump, 1 CPS) placed electively on percutaneous support because of poor baseline left ventricular function, 4 patients with emergency counterpulsation (2 patients who underwent emergency surgery and 2 patients with no-reflow who were managed with PTCA and nitroglycerin), and 1 patient on CPS who died. Temporary pacemakers were inserted in 2 patients (1.9%) because of bradycardia associated with transient no-reflow. Vas Angiographic follow-up was available in 83 of 99 patients (84%) who were discharged from the hospital after successful procedures (the 2 deaths occurred before angiographic follow-up was obtained). Quantitative angiography revealed a minimal lumen diameter of 1.4±0.8 mm, which corresponded to a diameter stenosis of 57±24%. The diameter of the reference segment was 3.2±0.8 mm, and the lesion length was 6.5±3.7 mm. If restenosis is defined as a diameter stenosis of more than 50%, then 51% of patients had angiographic evidence for restenosis at the time of follow-up angiography (Fig  3) . There was no significant difference in restenosis rates for patients treated with MRA for de novo (50%) or restenosis (54%) lesions. Discussion In the past few years, several new interventional devices have been developed to address the limitations of conventional balloon angioplasty. In fact, Food and Drug Administration approval for many of these devices has been granted or is imminent. However, the role of these devices with respect to each other and with respect to balloon angioplasty is still unknown. The evaluation of these devices is currently a major area of interest of a new National Heart, Lung, and Blood Institute Registry.1
Mechanism ofAction
Unlike other atherectomy devices that rely on tissue cutting and retrieval (directional atherectomy) or cutting and aspiration (extraction atherectomy), highspeed MRA with the Rotablator relies on abrasion and pulverization of atheroma.7 Although the Rotablator is usually classified as an atherectomy device, tissue displacement occurs by distal embolization rather than tissue removal. However, experimental studies suggest that microparticle dimensions are dependent on the size of the burr and the speed of rotation, and it is generally assumed that in human coronary use, the majority of microparticles are less than 5 gm in diameter.12 Al- though particles of this size should pass harmlessly into the microcirculation, distal embolization leading to myocardial infarction has been reported. 13 The relative contribution of tissue pulverization versus the "Dotter" effect (mechanical dilation of the lesion) is unknown.
Acute Results
Although the Rotablator successfully crossed all target lesions, the absolute magnitude of lumen enlargement was disappointing. After initial MRA, the average minimal lumen diameter was only 1.4±0.7 mm, which was similar to the minimal lumen diameter of 1.51 and 1.46 mm reported independently by Teirstein and colleagues13 and Bertrand and colleagues,14 respectively. The residual diameter stenosis of 54±23% after MRA was similar to the 42% residual stenosis reported by Bertrand and colleagues.14 Although Teirstein and colleagues13 reported a residual diameter stenosis of 37% after MRA, this was due to selection of smaller vessels with a reference diameter of less than 3 mm, in contrast to the reference diameter of 3.2±0.8 mm in the present study.
Although many investigators report the success of intervention on the basis of change in percent stenosis or residual diameter stenosis, these success rates are dependent on several factors that are independent of the device per se, including the severity of the baseline stenosis and the size of the reference segment. Nevertheless, when analyzed in these terms, 50% of the treated lesions had a residual stenosis of more than 50% after MRA and only 44% of lesions improved by 20% or more after MRA. However, considering the small burr diameter used in coronary arteries, the relative lumen enlargement after MRA was excellent. The RLD-D ratio of 0.91 indicates that the magnitude of lumen enlargement was equal to 91% of the diameter of the burr (ie, a 2-mm burr resulted in a lumen diameter of 1.82 mm). This suggests that 9% of the burr diameter was "lost" due to elastic recoil or spasm, in contrast to the 30% acute loss of diameter immediately after PTCA (RLD-D ratio, 0.7) and the 20% acute loss of diameter immediately after laser balloon angioplasty (RLD-D ratio, 0.8). lumen enlargement after PTCA were not reported by Bertrand and colleagues14 and PTCA was not used by Teirstein and colleagues,13 PTCA in the present study was used both as an adjunct to MRA to achieve better lumen enlargement (minimal lumen diameter increased to 2.3±0.7 mm and diameter stenosis decreased to 30±20% after PTCA) and as a means for salvaging MRA-induced complications in 24 of 46 lesions (52%). Although the final diameter stenosis after adjunctive PTCA was similar to the 30% to 40% residual stenosis that has been reported after PTCA alone,3-6 the types of lesions may not be comparable. Given the complexity of the lesions treated by MRA in this study, it is possible that MRA could have facilitated the results of subsequent PTCA,16 but this remains to be demonstrated in future investigations. Lesion Morphology After MRA By "polishing" the arterial lumen, the hope was that MRA would result in a smoother, dissection-free lumen compared with PTCA. The incidence of dissection in this study was approximately 30%, which is somewhat lower than the 40% to 50% rate reported for PTCA17-19 but somewhat higher than the 2% to 11% rate of dissection reported for directional atherectomy. 19, 20 Safety Several important observations were made regarding the safety of MRA. First, severe dissection leading to abrupt closure (11.2%), distal embolization leading to no-reflow (6.1%), and severe coronary vasospasm (13.8%) were more common after MRA than suggested by recent reports of PTCA for complex lesions.20,21 In a series of 1000 lesions treated by PTCA (92% of these lesions were type B or C), abrupt closure was observed in only 3.5%, and the overall incidence of serious complications was less than 2%.22 Second, the majority (42 of 49, 86%) of the angiographic complications observed in this study were managed successfully by a combination of PTCA, vasodilators, and thrombolytic agents. Third, despite these angiographic observations, the clinical sequelae of death (1.0%) and emergency bypass graft surgery (1.9%) compare favorably with that of PTCA, but the combined incidence (7.1%) of Q-wave and non-Q-wave myocardial infarctions is higher than expected for patients undergoing PTCA. The lower incidence of non-Q-wave myocardial infarction (2.9%) in this study compared with that of Teirstein and colleagues (19%) may have been due to the selection of longer lesions (mean lesion length, 31 mm) in that study13 compared with ours (mean lesion length, 6.6 mm). Finally, although the lesions targeted by directional atherectomy may be different than those for MRA, the incidence of serious clinical complications is similar.23
Restenosis
The overall restenosis rate of 51% for patients treated with MRA (with or without adjunctive PTCA) is similar to the restenosis rate after MRA of 59% reported by Teirstein and colleagues13 but is higher than the restenosis rate of 31% reported by Bertrand 
Conclusions
High-speed MRA with the Rotablator can be applied successfully to a subset of patients with complex lesion morphology. However, the development of severe dissection, no-reflow, or inadequate lumen enlargement mandates the need for adjunctive or salvage balloon angioplasty in the majority of patients to achieve optimal angiographic and clinical results. The combination of MRA and PTCA does not appear to have any impact on restenosis.
